Cytovac to re-enter abandoned disease area
The Danish biotech company Cytovac had abandoned its plans of entering a specific cancer indication with its main asset Alecsat, when a phone call from Iceland changed everything.
BY LONNI LYNGE
It is more or less down to pure coincidence that the Danish biotech company Cytovac is set to target skin cancer with its main asset Alecsat, an immunotherapy originally aimed at a rare and highly aggressive type of brain cancer known as Glioblastoma.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Cytovac opts for Swedish brain cancer trial
For abonnenter
CytoVac reinforces board room
For abonnenter
CytoVac is talking to potential partners
For abonnenter
